Treatment Outcomes.

To meet global healthcare demands, a tertiary care teaching hospital studies pulmonary TB patients' drug use. Respiratory TB is a major problem in poor nations. The study optimizes anti-tuberculosis medicine use to improve patient outcomes and prevent transmission. Due to dosage and duration, optimization influences drug effectiveness, side effects, and resistance. The study emphasizes medication adherence and patient compliance to prevent treatment failure and drug-resistant strains. Pulmonary TB is infectious yet hard to identify due to its mild symptoms. Diagnostics and treatment include clinical and laboratory tests and long-term antibiotics. Immunization and latent TB therapy prevent TB. Healthcare professionals, governments, and international organizations must collaborate to eliminate pulmonary TB. During the 8-month study period, a group of 600 patients with PTB was examined. The group of 30-50 years revealed more males than females with PTB among them. The drug isoniazid was by far the most heavily recommended first-line treatment. In contrast to Isoniazid, it couldn’t adhere to Levofloxacin efficiently. In one of the tests, it was observed that there were undernourished persons that are protein and micronutrient deficient also. The study showed most mental comorbidities as depression. Multidrug resistance preceded non-resistance. From this study, we determined the high rate of PTB relapse and partial healing. The study suggested approaches to improving protein-energy deficit and mental depression as well as to multi-drug resistance and for treating patients. The study suggested collaboration and research to reduce PBA mortality rates and produce tablets, medications, and treatments to help doctors treat, change diets, and counsel PTB patients.